Evidence map›Paper›PMID 41562082›Full record

ArticleFrontiers in immunology2025

Guizeng Zhao, Can Guo, Xiaoyang Li, Lei Tan, Xueyang Chen, Feng Tian, Lili Zhang, Xia Wang, Junwei Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guizeng ZhaoThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Can GuoThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Xiaoyang LiThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Lei TanThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Xueyang ChenThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Feng TianThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Lili ZhangThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Xia WangThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.
Junwei CuiThe First Affiliated Hospital of Xinxiang Medical University, Weihui, Xinxiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mycobacterium tuberculosis (MTB) evades host immunity and maintains chronic infection, in part by reprogramming macrophage function. The chemokine Methods: Using the H37Ra-infected mouse model, the expression of MTB virulence marker ESAT-6 and autophagy marker Beclin-1 was assessed. Transcriptome analysis was performed to identify Results: Conclusion: The

Indexed as

Chemokine CCL2Macrophage ActivationMacrophagesMycobacterium tuberculosisReceptors, CCR2TuberculosisAnimalsApoptosisBacterial ProteinsDisease Models, AnimalImmune ToleranceMiceMice, Inbred C57BLSignal TransductionBacterial ProteinsCcl2 protein, mouseCcr2 protein, mouseChemokine CCL2Receptors, CCR2H37RaimmunityM2 macrophage polarizationMCP-1/CCR2 axismycobacterium tuberculosis

Identifiers

PMID41562082
PMCPMC12813122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.